Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) updated its presentation time at the J.P. Morgan Annual Healthcare Conference to 11:15 am PST on Tuesday, January 13, 2026. CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations Tracy Krumme will participate. A live webcast and replay will be available via the company’s Investor Relations "Events" page. Investors seeking one-on-one meetings should contact their banking representatives.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FTRE declined 0.29%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
FTRE slipped 0.29% while peers showed mixed moves: ATAI down 0.5%, CRMD down 14.02%, EYPT down 2.4%, MRVI up 0.26%, and QURE up 2.07%, suggesting stock-specific trading rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Conference participation | Neutral | +5.5% | Announced J.P. Morgan conference presentation and webcast access details. |
| Dec 10 | Equity inducement awards | Neutral | +5.2% | Granted 245,000 RSUs to new hires under inducement plan. |
| Dec 04 | Strategic collaboration | Positive | -0.7% | Announced SCTbio collaboration to align CDMO and CRO services. |
| Nov 25 | Conference participation | Neutral | +7.0% | Outlined CEO/CFO participation in Citi and Evercore conferences. |
| Nov 24 | Debt tender offer | Positive | +9.6% | Completed $75.743M senior notes tender funded with cash on hand. |
Recent news often saw strong positive price reactions, but moves frequently diverged from the neutral-to-positive tone of announcements.
Over the last few months, Fortrea issued several corporate updates and financial actions. Conference participation notices in November–January regularly coincided with positive moves, including price reactions of 5.54% and 6.95%. A December 2025 inducement RSU grant and a strategic collaboration on December 4, 2025 also drew mixed reactions, while completion of a $75.743 million senior notes tender on November 21, 2025 saw a 9.63% gain. Today’s scheduling update for the J.P. Morgan conference fits this pattern of frequent investor-relations communications.
Market Pulse Summary
This announcement updates Fortrea’s presentation time to 11:15 am PST on January 13, 2026 at the J.P. Morgan Healthcare Conference, reiterating webcast access and optional one-on-one meetings via banking representatives. It follows a series of conference appearances and investor-focused communications in recent months. Investors tracking the story may focus more on any commentary delivered at the conference and on ongoing execution against prior financial and strategic disclosures than on this scheduling change itself.
Key Terms
contract research organization technical
AI-generated analysis. Not financial advice.
DURHAM, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced an updated presentation time of 11:15 am PST on Tuesday, January 13, 2026, at the J.P. Morgan Annual Healthcare Conference (San Francisco).
CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the conference. The live webcast and replay can be accessed through the “Events” section of Fortrea’s Investor Relations website. Investors interested in one-on-one meetings should contact their banking representatives.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts:
Tracy Krumme (Investors) – 984-385-6707, Tracy.Krumme@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com